1-3 of 3
Keywords: Sunitinib
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2020) 43 (7-8): 333–339.
Published Online: 15 June 2020
... still to be defined. Methods: In this small prospectively randomized phase IIa multicenter trial, we investigated temsirolimus (TEM) versus sunitinib (SUN) as first-line therapy in patients with metastatic nccRCC. The patients were randomized 1:1 to either TEM in a dose of 25 mg i.v. once a week or SUN...
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2016) 39 (12): 811–816.
Published Online: 18 November 2016
... up to a dose of 400 mg (orally (p.o.))/day for metastatic disease, and for up to 3 years for adjuvant treatment of high-risk GISTs. Sunitinib can be prescribed and is reimbursed after imatinib failure, and regorafenib has recently become available for routine use. Gastrointestinal stromal tumors...
Journal Articles
Subject Area:
Oncology
Oncol Res Treat (2014) 37 (3): 124–126.
Published Online: 26 February 2014
... with metastatic and progressive EHE of the liver. She was successfully treated with daily administration of sunitinib malate, an oral multi-target tyrosine kinase inhibitor, which particularly targets vascular endothelial growth factor (VEGF) receptors. Stabilization has lasted 6 years. We discuss the rationale...